Products and pipelines 

Adjuvant Products

Adjuvant for prophylactic vaccine

It is the pre-screened adjuvant that shows the strongest but most safest parenteral as well as mucosal immune response when injected with an antigen. It is sterile and ready for injection. Simply mix with your source of antigen and inject to your choice of testing animal. The dose is 5 ug/mouse for IP/IN/IV and 10 ug/mouse for SC/IM/ID.   It shows a potent protection activity against influenza virus either by IM or IN.

 Product information

1. AVA001/ 1 mg (for 200 mice injection)/$ 990

2. AVA002/10 mg (for 2,000 mice injection)/ $ 3,900

 For more detail of the product including a contract or bulk supply, please contact to us at adjuvant@5minDNA.com.

Adjuvant for cancer vaccine

It is the pre-screened adjuvant that shows the strongest therapeutic effect in a mouse melanoma model through Th-1 and Th-2 immune system.  It potentiates the effect of cancer immunotherapy when injected with an cancer antigen. The antigen and adjuvant mixture shows potent anti-cancer as well as anti-metastatic effect. It is sterile and ready for injection. Simply mix with your cancer antigen and inject to your choice of testing animal. The source of antigen can be from a peptide to tumor lysate. The dose is 5 ug/mouse for IP/IN/IV and 10 ug/mouse for SC/IM/IN. With the significant induction of Th-1 immune response, the vaccine shows potent cytolytic effect to the cancer cells through the CD8+ cells.

Product information

1. ACA001 / 1 mg (for 200 mice injection)/$ 990

2. ACA002/10 mg (for 2,000 mice injection)/ $ 3900

For more detail of the product including a contract or bulk supply, please contact to us at adjuvant@5minDNA.com.

Pipelines 

After all time and money consuming endeavor, the soluble epitope is recognized as processed end product of immune system instead of identity of target pathogen.  If each unique epitope and our novel adjuvant is mixed, they form a heat stable and a potent immune stimulating nano-complex.  The complex is homogeneous with the fixed size of 400 nm which is misunderstood as a invading viral particle to immune systems. These platform technology can be extended to diverse area of vaccines from infectious diseases to T-cell based cancer immunotherpay. 

The leading platform technology can be applied to every single vaccine development by adopting each unique epitope.  The vaccine complex can be loaded with multiple epitopes target diverse serotypes of pathogen or target diseases.  

Broad spectrum immune booster

  1. Nasal spray for immune boosting 
  2. Activate NK , DC, and Macrophage cells
  3. Broad spectrum of protection against diverse pathogens especially to respiratory virus
  4. For emergency application without identification of pathogen or in the absence of vaccine 
  5. Pre-clinical trial: 1st Q of 2019 in Korea
  6. Clinical trial I: 4th Q of 2019 in Korea for Universal Flu Prevention
  7. Clinical trial I: 4th Q of 2019 in Australia for Chronic Fatigue Syndrome (CFS)

Universal Flu Vaccine  

  1. Nasal spray vaccine for flu
  2. Peptide based cold chain free vaccine 
  3. Universal flu vaccine 
  4. Under optimization 
  5. Pre-clinical trial: 2nd Q of 2019
  6. Clinical trial I: 1st Q of 2020 in Korea as universal flu vaccine

HER2 breast cancer vaccine 

  1. HER2 target breast cancer vaccine  
  2. Peptide based cold chain free vaccine
  3. A preventative/therapeutic vaccine 
  4. Under optimization
  5. Pre-clinical trial: 2nd Q of 2019
  6. Clinical trial I: 1st Q of 2020 in Korea as HER2 breast cancer vaccine

Tuberculosis Vaccine 

  1. Multi-Epitope based peptide vaccine
  2. Nasal spray vaccine for tuberculosis 
  3. Cold chain free vaccine for self administration
  4. Under efficacy optimization
  5. Pre-clinical: 3rd Q of 2019